Legal & General Group
VIGL

Legal & General Group’s Vigil Neuroscience VIGL Stock Holding History

Legal & General Group’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,554
Closed -$5.27K – 3513
2024
Q1 		$5.27K Hold
1,554
– – ﹤0.01% 3292
2023
Q4 		$5.27K Hold
1,554
– – ﹤0.01% 3320
2023
Q3 		$8.51K Hold
1,554
– – ﹤0.01% 3301
2023
Q2 		$14.6K Buy
+1,554
New +$14.7K ﹤0.01% 3233
2022
Q2 		– Sell
-634
Closed -$4K – 3663
2022
Q1 		$4K Buy
+634
New +$8.37K ﹤0.01% 3524

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Legal & General Group's VIGL Position: Q2 2024 in Review

Legal & General Group sold out of Vigil Neuroscience (VIGL) in Q2 2024, closing a stake of 1,554 shares — an estimated $5.27K sold.

Legal & General Group first reported a position in VIGL in Q1 2022 and held it in 5 quarters. The position peaked at $14.6K in Q2 2023. 58 funds tracked by Wall St. Rank hold VIGL as of Q2 2024.

  • Legal & General Group reported no remaining Vigil Neuroscience position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 1,554 Vigil Neuroscience shares in Q2 2024, an estimated $5.27K.
  • Legal & General Group first reported a position in Vigil Neuroscience in Q1 2022 and held it in 5 quarters.
  • Legal & General Group's Vigil Neuroscience position peaked at $14.6K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.